TransQST Webinar Series on Model Implementation
A new hands-on webinar format launched in January 2021
The TransQST consortium is proud to present a new Webinar series on Model Implementation starting on January 26, 2021. The aim of this activity is to catalyse discussions on the implementation of consortium-developed models in the pharma industry as part of the project sustainability. In order to focus the webinars on the right questions and […]
Read moreMore TagTransQST Webinar series – Journal Club by ULIV researchers
A transcriptional response assay for predicting bioactivation-mediated drug-induced liver injury
A new edition of the TransQST Webinar series 2020 took place on Monday November 9th with a presentation delivered by Rowena Sison-Young (ULIV). Accurately predicting the liability of drug candidates to cause hepatotoxicity remains a challenge for the pharmaceutical industry. This is a consequence of the complex nature of this disease which encompasses several mechanisms, […]
Read moreMore Tag6th TransQST General Assembly Meeting
TransQST GAM6 took place as a virtual meeting in October 2020
The 6th TransQST General Assembly Meeting was held on 5th and 6th of October 2020 as a 2-day virtual conference. Close to 100 delegates of the TransQST consortium joined the event, centred on the implementation of the models and work carried out within the different work packages, as well as on defining future dissemination and […]
Read moreMore TagTransQST present at Science Is Wonderful! exhibition
TransQST work presented at the virtual Science Is Wonderful! exhibition
TransQST researchers of the University of Oxford participated in the European Research and Innovation Days´ virtual exhibition Science Is Wonderful! held on 22-24 of September 2020. Part of the second edition of European Research and Innovation Days, the Science is Wonderful! exhibition aims to bring the world of science, research, and innovation to the public. This year´s exhibition was […]
Read moreMore TagTransQST Webinar series – A guided tour to the use of organoids for compound efficacy and adversity
The latest advances in the use of organoids were brought to TransQST partners and external participants by the OcellO crew.
The TransQST Webinar series 2020 resumed on Monday September 14th with a presentation delivered by the Senior Director of OcellO BV, Bram Herpers, on the use of organoids in drug testing. OcellO is a CRO offering drug testing services in 3D cultured human tissues. OcellO screens, identifies and profiles potential drugs for efficacy and adverse […]
Read moreMore Tag